Skip To Main Content
Romualdo Barroso-Sousa on Muck Rack

Romualdo Barroso-Sousa

As seen in: Nature, Wiley Online Library, Therapeutic Advances in Medical Oncology, MDPI, JAMA Oncology, ONCOLOGY journal, Future Medicine, Cancer Treatment Reviews, Clinical Breast Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Romualdo

Contact Romualdo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Role of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer treated with KEYNOTE-522 in real-world setting

|
By Renata Colombo Bonadio, Flávia Cavalcanti Balint, Federico Waisberg, Zenaide Silva de Souza, Débora de Melo Gagliato, Mayana Lopes de Brito, Daniele Assad-Suzuki, Daniela Dornelles Rosa, Laura Testa, María Ferreira, Isadora Martins de Sousa, Matheus de Oliveira Andrade, Mariana Gouveia, Fernanda Madasi, José Bines, Candice Lima Santos, Monique Celeste Tavares, Maira Tavares, Mariana Monteiro, Bruna Zucchetti, Anezka Ferrari, Gilmara Resende, Vanesa López, VANESA lOPEZ, Solange Moraes Sanches, Paulo M Hoff, Romualdo Barroso-Sousa, Constanza Perez de la Puente
| Nature Verified
Abstract Tumor-infiltrating lymphocytes (TILs) are established prognostic and predictive biomarkers in early-stage triple-negative breast cancer (eTNBC), yet their role in patients treated with the KEYNOTE-522 (KN522) regimen remains underexplored.
Open in Who Shared Issue with article?

Beyond a single disease: review of rare histological subtypes of triple-negative breast cancer with implications for prognosis and treatment

|
By Mariana Gouveia, Renata Colombo Bonadio, Romualdo Barroso-Sousa, Kartik Rathi, Uma Krishnamurti, Maryam B. Lustberg, Adriana Kahn, Mohamed Kahila
| Nature Verified
Abstract Triple-negative breast cancer (TNBC) is commonly approached as a single clinical entity despite marked biological heterogeneity. A subset of cases corresponds to rare histologic subtypes that display distinct molecular drivers, immune microenvironments, and clinical behavior. In this Review, we summarize the clinicopathologic and molecular features of rare TNBC histologies and discuss emerging therapeutic vulnerabilities.
Open in Who Shared Issue with article?

Differential response and survival across rare histologic subtypes of triple-negative breast cancer following neoadjuvant chemo-immunotherapy

|
By Romualdo Barroso-Sousa, Mariana Gouveia, Monica Varela, Laura Testa, Monique Celeste Tavares, Flávia Cavalcanti Balint, Zenaide Silva de Souza, Débora de Melo Gagliato, Mayana Lopes de Brito, Melina Winocur, Daniele Assad-Suzuki, Daniela Dornelles Rosa, Isadora Martins de Sousa, Matheus de Oliveira Andrade, Fernanda Madasi, José Bines, Candice Lima Santos, Maira Tavares, Mariana Monteiro, Bruna Zucchetti, Anezka Ferrari, Gilmara Resende, Solange Moraes Sanches, Paulo M Hoff, Gonzalo Gomez Abuin, Renata Colombo Bonadio, Carlos Gallina
| Nature Verified
Abstract Special histologic subtypes of triple-negative breast cancer (TNBC) are biologically distinct, yet their outcomes in the immunotherapy era remain undefined. We analyzed 823 patients with early-stage TNBC treated with pembrolizumab plus chemotherapy in the multicenter real-world Neo-Real/GBECAM-0123 cohort.
Open in Who Shared Issue with article?
See all 19 articles